Welcome to The Visible Embryo

Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact


Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo in 1993 as a first generation internet teaching tool consolidating human embryology teaching for first year medical students.

Today, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than 1 million visitors each month. The field of early embryology has grown to include the identification of the stem cell as not only critical to organogenesis in the embryo, but equally critical to organ function and repair in the adult human.

The identification and understanding of genetic malfunction, inflammatory responses, and the progression in chronic disease, begins with a grounding in primary cellular and systemic functions manifested in the study of the early embryo.


WHO International Clinical Trials Registry Platform
The World Health Organization (WHO) has created a new Web site to help researchers, doctors and patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Archive
Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFemale Reproductive SystemFertilizationThe Appearance of SomitesFirst TrimesterSecond TrimesterThird TrimesterFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterDevelopmental Timeline
Click weeks 0 - 40 and follow fetal growth
Search artcles published since 2007

March 6, 2013--------News Archive Return to: News Alerts


Parkinson's disease Parkinson's disease is a disorder of the brain that leads to shaking
(tremors) and difficulty with walking, movement, and coordination.
Symptoms may be mild at first.


While LRRK2 mutations are the most common genetic cause of Parkinson's, it is too
early to tell whether these findings, and therapies that might stem from them, would
apply to patients with non-familial Parkinson's, the more common form of the disease.










WHO Child Growth Charts

       

Faulty Protein Digestion in Neurons Cause of Familial Parkinson's

Findings point to an intracellular system breakdown that normally would prevent the protein alpha-synuclein from reaching toxic levels in dopamine-producing neurons

Researchers at Columbia University Medical Center (CUMC), with collaborators at the Albert Einstein College of Medicine of Yeshiva University, have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells.


The mutations block an intracellular system that normally
prevents a protein called alpha-synuclein from reaching toxic
levels in dopamine-producing neurons.

The findings suggest that interventions aimed at enhancing
this digestive system, or preventing its disruption, may prove
valuable in the prevention or treatment of Parkinson's.


The study was published March 3 in the online edition of the journal Nature Neuroscience.

Parkinson's disease is characterized by the formation of Lewy bodies (which are largely composed of alpha-synuclein) in dopamine neurons. In 1997, scientists discovered that a mutation in alpha-synuclein can lead to Lewy body formation. "But alpha-synuclein mutations occur in only a tiny percentage of Parkinson's patients," said co-lead author David L. Sulzer, PhD, professor of neurology, pharmacology, and psychiatry at CUMC. "This meant that there must be something else that interfered with alpha-synuclein in people with Parkinson's."

Dr. Sulzer and his colleagues suspected that a gene called leucine-rich repeat kinase-2 (LRRK2) might be involved. LRRK2 mutations are the most common mutations to have been linked to Parkinson's. The current study aimed to determine how these mutations might lead to the accumulation of alpha-synuclein.

"We found that abnormal forms of LRRK2 protein disrupt a critical protein-degradation process in cells called chaperone-mediated autophagy," said Dr. Sulzer. "One of the proteins affected by this disruption is alpha-synuclein. As this protein starts to accumulate, it becomes toxic to neurons." Delving deeper, the researchers found that LRRK2 mutations interfere with LAMP-2A, a lysosome membrane receptor that plays a key role in lysosome function.


Chaperone-mediated autophagy, or CMA, is responsible
for transporting old or damaged proteins from the cell body
to the lysosomes, where they are digested into
amino acids and then recycled.

In 2004, Dr. Sulzer and the current paper's other
co-lead author, Ana Maria Cuervo, MD, PhD, professor
of developmental & molecular biology, anatomy & structural
biology, and of medicine at Albert Einstein College
of Medicine of Yeshiva University, showed that alpha-
synuclein is degraded by the CMA pathway.


"Now that we know this step that may be causing the disease in many patients, we can begin to develop drug treatments or genetic treatments that can enhance the digestion of these disease-triggering proteins, alpha-synuclein and LRRK2, or that remove alpha-synuclein," said Dr. Sulzer.

While LRRK2 mutations are the most common genetic cause of Parkinson's, it is too early to tell whether these findings, and therapies that might stem from them, would apply to patients with non-familial Parkinson's, the more common form of the disease.

"Right now, all we can say is that it looks as though we've found a fundamental pathway that causes the buildup of alpha-synuclein in people with LRRK2 mutations and links these mutations to a common cause of the disease. We suspect that this pathway may be involved in many other Parkinson's patients," said Dr. Sulzer.

The study involved mouse neurons in tissue culture from four different animal models, neurons from the brains of patients with Parkinson's with LRRK2 mutations, and neurons derived from the skin cells of Parkinson's patients via induced pluripotent stem (iPS) cell technology. All the lines of research confirmed the researchers' discovery.

The paper is titled "Interplay of LRRK2 with chaperone-mediated autophagy." The other contributors are Samantha J. Orenstein (Einstein), Sheng-Han Kuo (CUMC), Inmaculada Tasset (Einstein), Esperanza Arias (Einstein), Hiroshi Koga (Einstein), Irene Fernandez-Carasa (University of Barcelona, Barcelona Spain), Etty Cortes (CUMC), Lawrence S. Honig (CUMC), William Dauer (University of Michigan, Ann Arbor, MI), Antonella Consiglio (University of Barcelona and University of Brescia, Brescia, Italy), and Angel Raya (Insitucio Catalana de Recerca I Estudies Avancas and Center for Networked Biomedical Research on Bioengineering, Biomaterials and Nanomedicine, Barcelona, Spain).

The collaboration of Sulzer and Cuervo was supported by a Udall Center of Excellence for Research in Parkinson's Disease of the NIH National Institute of Neurological Disorders and Stroke. This work was further supported by grants from the JPB Foundation, the National Institute on Aging (AG031782 and AG08702); the Rainwater Foundation; the Beatrice and Roy Backus Foundation; the Parkinson's Disease Foundation; Fondazione Guido Berlucchi; and Centers for Networked Biomedical Research, Ministry of Economy and Competitiveness and by a Hirschl/Weill-Caulier Career Scientist Award and a gift from Robert and Renee Belfer.

The authors declare no financial or other conflicts of interest.

Columbia University Medical Center provides international leadership in basic, pre-clinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia's College of Physicians and Surgeons was the first institution in the country to grant the MD degree and is among the most selective medical schools in the country. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest in the United States. Its physicians treat patients at multiple locations throughout the tri-state area, including the NewYork-Presbyterian/Columbia campus in Washington Heights, the new ColumbiaDoctors Midtown location at 51 W. 51st St. in Manhattan, and the new ColumbiaDoctors Riverdale practice. For more information, visit http://www.cumc.columbia.edu or http://www.columbiadoctors.org

Original article: http://www.cumc.columbia.edu/news-room/2013/03/05/improper-protein-digestion-in-neurons-identified-as-a-cause-of-familial-parkinsons/?utm_source=rss&utm_medium=rss&utm_campaign=improper-protein-digestion-in-neurons-identified-as-a-cause-of-familial-parkin